Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration
Abstract Introduction To analyze visual and anatomical outcomes in patients switched to brolucizumab and previously treated with other intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for exudative neovascular age-related macular degeneration (nAMD). These outcomes were was as...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Ophthalmology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-025-01141-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133428884733952 |
|---|---|
| author | Federico Beretta Ilaria Zucchiatti Riccardo Sacconi Federico Fantaguzzi Stefano Lingardo Francesco Bandello Giuseppe Querques |
| author_facet | Federico Beretta Ilaria Zucchiatti Riccardo Sacconi Federico Fantaguzzi Stefano Lingardo Francesco Bandello Giuseppe Querques |
| author_sort | Federico Beretta |
| collection | DOAJ |
| description | Abstract Introduction To analyze visual and anatomical outcomes in patients switched to brolucizumab and previously treated with other intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for exudative neovascular age-related macular degeneration (nAMD). These outcomes were was assessed in the real-world setting of a tertiary center with a follow-up period of 2 years. Methods This retrospective longitudinal study included 29 eyes of 24 patients with exudative nAMD previously treated with at least three injections of another intravitreal anti-VEGF molecule. The eyes were then treated with brolucizumab for at least 24 months following the switch. A pro re nata (“as needed”) therapeutic regimen was followed in our clinic between January 2021 and June 2024, during which time clinical and anatomical parameters were evaluated, and possible adverse events were recorded. Results After 24 months of treatment with brolucizumab, patients showed a significant reduction in central macular thickness (P = 0.001) and choroidal thickness (P < 0.001). Visual acuity remained stable during the follow-up period. "Poor responders" had longer disease duration and had received more injections before the switch than "good responders." Adverse events included one subretinal hemorrhage and one intraocular inflammation across 302 injections. Conclusions Treatment with brolucizumab is effective in patients previously treated with other therapeutic molecules. The best outcomes were achieved in patients who switched therapy to brolucizumab early in their disease. Treatment with brolucizumab in this population demonstrated an acceptable risk profile, with only one intraocular inflammatory event out of 302 intravitreal injections. |
| format | Article |
| id | doaj-art-7f74f564aa0545c5b07a403f695702dc |
| institution | OA Journals |
| issn | 2193-8245 2193-6528 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Ophthalmology and Therapy |
| spelling | doaj-art-7f74f564aa0545c5b07a403f695702dc2025-08-20T02:31:58ZengAdis, Springer HealthcareOphthalmology and Therapy2193-82452193-65282025-04-011461325133510.1007/s40123-025-01141-yTwo-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular DegenerationFederico Beretta0Ilaria Zucchiatti1Riccardo Sacconi2Federico Fantaguzzi3Stefano Lingardo4Francesco Bandello5Giuseppe Querques6School of Medicine, Vita-Salute San Raffaele UniversitySchool of Medicine, Vita-Salute San Raffaele UniversitySchool of Medicine, Vita-Salute San Raffaele UniversitySchool of Medicine, Vita-Salute San Raffaele UniversitySchool of Medicine, Vita-Salute San Raffaele UniversitySchool of Medicine, Vita-Salute San Raffaele UniversitySchool of Medicine, Vita-Salute San Raffaele UniversityAbstract Introduction To analyze visual and anatomical outcomes in patients switched to brolucizumab and previously treated with other intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for exudative neovascular age-related macular degeneration (nAMD). These outcomes were was assessed in the real-world setting of a tertiary center with a follow-up period of 2 years. Methods This retrospective longitudinal study included 29 eyes of 24 patients with exudative nAMD previously treated with at least three injections of another intravitreal anti-VEGF molecule. The eyes were then treated with brolucizumab for at least 24 months following the switch. A pro re nata (“as needed”) therapeutic regimen was followed in our clinic between January 2021 and June 2024, during which time clinical and anatomical parameters were evaluated, and possible adverse events were recorded. Results After 24 months of treatment with brolucizumab, patients showed a significant reduction in central macular thickness (P = 0.001) and choroidal thickness (P < 0.001). Visual acuity remained stable during the follow-up period. "Poor responders" had longer disease duration and had received more injections before the switch than "good responders." Adverse events included one subretinal hemorrhage and one intraocular inflammation across 302 injections. Conclusions Treatment with brolucizumab is effective in patients previously treated with other therapeutic molecules. The best outcomes were achieved in patients who switched therapy to brolucizumab early in their disease. Treatment with brolucizumab in this population demonstrated an acceptable risk profile, with only one intraocular inflammatory event out of 302 intravitreal injections.https://doi.org/10.1007/s40123-025-01141-yAge-related macular degenerationAnti-vascular endothelial growth factorBrolucizumabFluid analysisIntraocular inflammationSwitch therapy |
| spellingShingle | Federico Beretta Ilaria Zucchiatti Riccardo Sacconi Federico Fantaguzzi Stefano Lingardo Francesco Bandello Giuseppe Querques Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration Ophthalmology and Therapy Age-related macular degeneration Anti-vascular endothelial growth factor Brolucizumab Fluid analysis Intraocular inflammation Switch therapy |
| title | Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration |
| title_full | Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration |
| title_fullStr | Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration |
| title_full_unstemmed | Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration |
| title_short | Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration |
| title_sort | two years real world experience of a tertiary center with intravitreal brolucizumab switch for treatment of exudative neovascular age related macular degeneration |
| topic | Age-related macular degeneration Anti-vascular endothelial growth factor Brolucizumab Fluid analysis Intraocular inflammation Switch therapy |
| url | https://doi.org/10.1007/s40123-025-01141-y |
| work_keys_str_mv | AT federicoberetta twoyearsrealworldexperienceofatertiarycenterwithintravitrealbrolucizumabswitchfortreatmentofexudativeneovascularagerelatedmaculardegeneration AT ilariazucchiatti twoyearsrealworldexperienceofatertiarycenterwithintravitrealbrolucizumabswitchfortreatmentofexudativeneovascularagerelatedmaculardegeneration AT riccardosacconi twoyearsrealworldexperienceofatertiarycenterwithintravitrealbrolucizumabswitchfortreatmentofexudativeneovascularagerelatedmaculardegeneration AT federicofantaguzzi twoyearsrealworldexperienceofatertiarycenterwithintravitrealbrolucizumabswitchfortreatmentofexudativeneovascularagerelatedmaculardegeneration AT stefanolingardo twoyearsrealworldexperienceofatertiarycenterwithintravitrealbrolucizumabswitchfortreatmentofexudativeneovascularagerelatedmaculardegeneration AT francescobandello twoyearsrealworldexperienceofatertiarycenterwithintravitrealbrolucizumabswitchfortreatmentofexudativeneovascularagerelatedmaculardegeneration AT giuseppequerques twoyearsrealworldexperienceofatertiarycenterwithintravitrealbrolucizumabswitchfortreatmentofexudativeneovascularagerelatedmaculardegeneration |